Echinocandin use in lung transplant recipients.

Yamama Al JishiColeman RotsteinDeepali KumarAtul HumarLianne G SingerShaf KeshavjeeShahid Husain

Published in: Clinical transplantation (2018)

Our data suggest that echinocandins are utilized in approximately 18.3% of lung transplant recipients. They are the preferred second-line agents due to a lower adverse-effect profile compared to the azoles.

Keyphrases

big data
emergency department
machine learning
adverse drug